Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022
31 oct. 2022 16h05 HE
|
Intercept Pharmaceuticals, Inc.
Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid (OCA) in liver fibrosis due to NASH to be featured in late-breaker podium presentation Analysis...
Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022
25 oct. 2022 08h00 HE
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals to Participate in H.C. Wainwright’s 6th Annual NASH Investor Conference on October 17, 2022
12 oct. 2022 08h00 HE
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
30 sept. 2022 07h55 HE
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel...
Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning
21 sept. 2022 07h30 HE
|
Intercept Pharmaceuticals, Inc.
Outstanding debt reduced by 54% or $388.9 million and annual cash interest expense reduced by 58% or $13.6 million Company well-positioned to drive continued growth in PBC, progress NASH program,...
Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology
20 sept. 2022 12h45 HE
|
Intercept Pharmaceuticals, Inc.
Combined clinical trial and real-world data with six years of follow-up provides important evidence of efficacy Analysis compares findings from the Phase 3 POISE trial and open-label extension to...
Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
07 sept. 2022 08h00 HE
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel...
Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022
29 août 2022 08h00 HE
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals Announces Repurchase of Convertible Notes
19 août 2022 07h30 HE
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of...
Intercept Pharmaceuticals to Participate in B. Riley’s PBC Symposium on August 24, 2022
18 août 2022 08h00 HE
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...